Take part in an interesting OAB Research Study
3 May, 2017
At the recent European Association of Urology Conference in March our Business Director was approached by Sepi - a research student at Potsmouth University - and asked if the charity could help with a research project into improving diagnosis of Overactive Bladder. As always we are onlt o happy to help with reserch into one of the areas we are concerned about - especially if it helps our members and other sufferes.
Please click here for the questionnaire - and thank you for taking part.
Please find below more details about Sepi and the project:-
Dr Sepinoud Firouzmand
School of Pharmacy and Biomedical Sciences
University of Portsmouth
Our research team has recently identified five elements within urine that together are capable of diagnosing Overactive bladder (OAB), one of the most prevalent and bothersome bladder diseases. The identified OAB fingerprint (i.e. urinary biomarker panel) has a very high potential to be developed into a point-of-care / companion OAB diagnostic test (e.g. OAB dipstick test). We envisage the resulting diagnostic platform will offer the following highly significant benefits for the healthcare professionals, healthcare system and well-being of patients:
i) The test can be performed on a urine sample donated by the patient to their GP surgery and/or pharmacies; eliminating very expensive (around £1500 per patient per test) and invasive cystometry and cystoscopy; with the significant risks associated with anaesthesia required for cystoscopy.
ii) Considering the high sensitivity and specificity (>80%) of our urinary biomarker panel to OAB, the proposed point-of-care OAB test is expected to have significantly higher diagnostic accuracy than the current unreliable diagnostic methods.
iii) Better diagnosis and the means to regularly monitor patients will provide knowledge of the pathology; and the foundation for more effective treatments.
iv) Earlier diagnosis would mean earlier treatment and better outcomes, thus avoiding surgery-based second-line treatments (Botulinum toxin injections; sacral neuromodulation) with associated risks.
v) Improved treatment of OAB would greatly reduce the impact of this debilitating disease on patients and their carers – improving quality of life, reducing the number of falls as patients rush to the bathroom, thus reducing the incidence of the many associated comorbidities associated with OAB (e.g. depression, anxiety and loneliness).
I have recently joined ICURe, a programme funded by InnovateUK and HEFCE, which supports researchers with commercially-promising ideas to engage with their prospective target markets and to identify and approach their potential collaborating and partnering bodies. During our conversation at EAU you kindly offered to put a questionnaire on your website regarding the usefulness of this prospective test, for which I am very grateful.